Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N550K |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 N550K (corresponds to N549K in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550K results in increased Fgfr2 kinase activity (PMID: 32723837, PMID: 23908597) and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N550K |
Transcript | NM_022970.4 |
gDNA | chr10:g.121498520A>C |
cDNA | c.1650T>G |
Protein | p.N550K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001144914.1 | chr10:g.121487991A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488063A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121487991A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121487991A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121488063A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121488063A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498520A>C | c.1650T>G | p.N550K | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01888562 | Phase I | Ponatinib | Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | Withdrawn | 0 |